From Bench to Beside to Cure Spinal Cord Injury: Lost in Translation?

International Review of Neurobiology

Volumn 106, Issue , 2012, Pages 173-196

  Hug, Andreas ^a   Weidner, Norbert ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Regeneration clinical trial; Remyelination axon; Spinal cord injury

Indexed keywords

11C7 ANTIBODY; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 7B12 ANTIBODY; ATI355 ANTIBODY; BA 210; CYCLIN DEPENDENT KINASE INHIBITOR 1; EXOENZYME C3; FASUDIL; IN 1 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 11C7; MONOCLONAL ANTIBODY 7B12; MYELIN; NEP1-40 PEPTIDE; NOGO A ANTIBODY; PEPTIDE; PROTEIN NOGO A; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TACROLIMUS; UNCLASSIFIED DRUG; MYELIN PROTEIN; PROTEIN NOGO;

ARTICLE; CELL TRANSPLANTATION; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DRUG FATALITY; EMBRYONIC STEM CELL; GRAFT REJECTION; HUMAN; IMMUNOMODULATION; INFECTION; MACROPHAGE; MYELINATION; NONHUMAN; OLIGODENDROGLIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPINAL CORD INJURY; ANIMAL; BIOSYNTHESIS; GENETICS; MEDICAL RESEARCH; METHODOLOGY; NERVE FIBER; NERVE REGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; TRANSLATIONAL RESEARCH;

ANIMALS; AXONS; BIOMEDICAL RESEARCH; HUMANS; MYELIN PROTEINS; NERVE REGENERATION; SPINAL CORD INJURIES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84884312397     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407178-0.00008-9     Document Type: Chapter

References (76)

1. Abel R., Baron H., Casha S. Therapeutic anti-Nogo-A antibodies in acute spinal cord injury: Safety and pharmacokinetic data from an ongoing first-in-human trial 2011.
2. Alto L.T., Havton L.A., Conner J.M., et al. Chemotropic guidance facilitates axonal regeneration and synapse formation after spinal cord injury. Nature Neuroscience 2009, 12:1106-1113.
3. Anderson K.D. Targeting recovery: Priorities of the spinal cord-injured population. Journal of Neurotrauma 2004, 21:1371-1383.
4. Anderson D.K., Beattie M., Blesch A., et al. Recommended guidelines for studies of human subjects with spinal cord injury. Spinal Cord 2005, 43:453-458.
5. Basso D.M., Beattie M.S., Bresnahan J.C. A sensitive and reliable locomotor rating scale for open field testing in rats. Journal of Neurotrauma 1995, 12:1-21.
6. Blesch A., Tuszynski M.H. Spinal cord injury: Plasticity, regeneration and the challenge of translational drug development. Trends in Neurosciences 2009, 32:41-47.
7. Bomstein Y., Marder J.B., Vitner K., et al. Features of skin-coincubated macrophages that promote recovery from spinal cord injury. Journal of Neuroimmunology 2003, 142:10-16.
8. Bonner J.F., Connors T.M., Silverman W.F., et al. Grafted neural progenitors integrate and restore synaptic connectivity across the injured spinal cord. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2011, 31:4675-4686.
9. Bregman B.S., Kunkel-Bagden E., Schnell L., et al. Recovery from spinal cord injury mediated by antibodies to neurite growth inhibitors. Nature 1995, 378:498-501.
10. Cafferty W.B., Kim J.E., Lee J.K., et al. Response to correspondence: Kim et al., "axon regeneration in young adult mice lacking Nogo-A/B." Neuron 38, 187-199. Neuron 2007, 54:195-199.
11. Caroni P., Schwab M.E. Antibody against myelin-associated inhibitor of neurite growth neutralizes nonpermissive substrate properties of CNS white matter. Neuron 1988, 1:85-96.
12. Chan C.C., Khodarahmi K., Liu J., et al. Dose-dependent beneficial and detrimental effects of ROCK inhibitor Y27632 on axonal sprouting and functional recovery after rat spinal cord injury. Experimental Neurology 2005, 196:352-364.
13. Chen M.S., Huber A.B., van der Haar M.E., et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 2000, 403:434-439.
14. Crowe M.J., Bresnahan J.C., Shuman S.L., et al. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nature Medicine 1997, 3:73-76.
15. Curt A., Schwab M.E., Dietz V. Providing the clinical basis for new interventional therapies: Refined diagnosis and assessment of recovery after spinal cord injury. Spinal Cord 2004, 42:1-6.
16. Dergham P., Ellezam B., Essagian C., et al. Rho signaling pathway targeted to promote spinal cord repair. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2002, 22:6570-6577.
17. Dimou L., Schnell L., Montani L., et al. Nogo-A-deficient mice reveal strain-dependent differences in axonal regeneration. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2006, 26:5591-5603.
18. Domeniconi M., Cao Z., Spencer T., et al. Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron 2002, 35:283-290.
19. Fawcett J.W., Curt A., Steeves J.D., et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: Spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 2007, 45:190-205.
20. Fehlings M.G., Theodore N., Harrop J., et al. A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. Journal of Neurotrauma 2011, 28:787-796.
21. Filbin M.T. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nature Reviews. Neuroscience 2003, 4:703-713.
22. Fouad K., Klusman I., Schwab M.E. Regenerating corticospinal fibers in the Marmoset (Callitrix jacchus) after spinal cord lesion and treatment with the anti-Nogo-A antibody IN-1. The European Journal of Neuroscience 2004, 20:2479-2482.
23. Fournier A.E., Grandpre T., Strittmatter S.M. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature 2001, 409:341-346.
24. Freund P., Schmidlin E., Wannier T., et al. Nogo-A-specific antibody treatment enhances sprouting and functional recovery after cervical lesion in adult primates. Nature Medicine 2006, 12:790-792.
25. Garcia-Alias G., Barkhuysen S., Buckle M., et al. Chondroitinase ABC treatment opens a window of opportunity for task-specific rehabilitation. Nature Neuroscience 2009, 12:1145-1151.
26. Gledhill R.F., Harrison B.M., McDonald W.I. Demyelination and remyelination after acute spinal cord compression. Experimental Neurology 1973, 38:472-487.
27. Grandpre T., Li S., Strittmatter S.M. Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature 2002, 417:547-551.
28. Grandpre T., Nakamura F., Vartanian T., et al. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 2000, 403:439-444.
29. Hulsebosch C.E. Recent advances in pathophysiology and treatment of spinal cord injury. Advances in Physiology Education 2002, 26:238-255.
30. Illis L.S. Central nervous system regeneration does not occur. Spinal Cord 2012, 50:259-263.
31. Kaiser J. Embryonic stem cells. Researchers mull impact of Geron's sudden exit from field. Science 2011, 334:1043.
32. Kakulas B.A. A review of the neuropathology of human spinal cord injury with emphasis on special features. The Journal of Spinal Cord Medicine 1999, 22:119-124.
33. Keirstead H.S., Nistor G., Bernal G., et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2005, 25:4694-4705.
34. Kim J.E., Li S., Grandpre T., et al. Axon regeneration in young adult mice lacking Nogo-A/B. Neuron 2003, 38:187-199.
35. Kim J.E., Liu B.P., Park J.H., et al. Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury. Neuron 2004, 44:439-451.
36. Knoller N., Auerbach G., Fulga V., et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: Phase I study results. Journal of Neurosurgery. Spine 2005, 3:173-181.
37. Kwon B.K., Hillyer J., Tetzlaff W. Translational research in spinal cord injury: A survey of opinion from the SCI community. Journal of Neurotrauma 2010, 27:21-33.
38. Lammertse D.P., Jones L.A., Charlifue S.B., et al. Autologous incubated macrophage therapy in acute, complete spinal cord injury: Results of the phase 2 randomized controlled multicenter trial. Spinal Cord 2012, 50:661-671.
39. Lazarov-Spiegler O., Solomon A.S., Zeev-Brann A.B., et al. Transplantation of activated macrophages overcomes central nervous system regrowth failure. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 1996, 10:1296-1302.
40. Levine J.M., Reynolds R. Activation and proliferation of endogenous oligodendrocyte precursor cells during ethidium bromide-induced demyelination. Experimental Neurology 1999, 160:333-347.
41. Li S., Liu B.P., Budel S., et al. Blockade of Nogo-66, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2004, 24:10511-10520.
42. Li S., Strittmatter S.M. Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2003, 23:4219-4227.
43. Liebscher T., Schnell L., Schnell D., et al. Nogo-A antibody improves regeneration and locomotion of spinal cord-injured rats. Annals of Neurology 2005, 58:706-719.
44. Liu B.P., Fournier A., Grandpre T., et al. Myelin-associated glycoprotein as a functional ligand for the Nogo-66 receptor. Science 2002, 297:1190-1193.
45. Lord-Fontaine S., Yang F., Diep Q., et al. Local inhibition of Rho signaling by cell-permeable recombinant protein BA-210 prevents secondary damage and promotes functional recovery following acute spinal cord injury. Journal of Neurotrauma 2008, 25:1309-1322.
46. Lu P., Wang Y., Graham L., et al. Long-distance growth and connectivity of neural stem cells after severe spinal cord injury. Cell 2012, 150:1264-1273.
47. Maier I.C., Ichiyama R.M., Courtine G., et al. Differential effects of anti-Nogo-A antibody treatment and treadmill training in rats with incomplete spinal cord injury. Brain: A Journal of Neurology 2009, 132:1426-1440.
48. Mayor S. First patient enters trial to test safety of stem cells in spinal injury. BMJ 2010, 341:c5724.
49. Merkler D., Metz G.A., Raineteau O., et al. Locomotor recovery in spinal cord-injured rats treated with an antibody neutralizing the myelin-associated neurite growth inhibitor Nogo-A. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2001, 21:3665-3673.
50. Nishio Y., Koda M., Kitajo K., et al. Delayed treatment with Rho-kinase inhibitor does not enhance axonal regeneration or functional recovery after spinal cord injury in rats. Experimental Neurology 2006, 200:392-397.
51. Pinzon A., Marcillo A., Pabon D., et al. A re-assessment of erythropoietin as a neuroprotective agent following rat spinal cord compression or contusion injury. Experimental Neurology 2008, 213:129-136.
52. Rapalino O., Lazarov-Spiegler O., Agranov E., et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nature Medicine 1998, 4:814-821.
53. Richardson P.M., McGuinness U.M., Aguayo A.J. Axons from CNS neurons regenerate into PNS grafts. Nature 1980, 284:264-265.
54. Rupp R., Gerner H.J. Neuroprosthetics of the upper extremity-Clinical application in spinal cord injury and challenges for the future. Acta Neurochirurgica. Supplement 2007, 97:419-426.
55. Schnell L., Schwab M.E. Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature 1990, 343:269-272.
56. Schuld C., Wiese J., Hug A., et al. Computer implementation of the international standards for neurological classification of spinal cord injury for consistent and efficient derivation of its subscores including handling of data from not testable segments. Journal of Neurotrauma 2012, 29:453-461.
57. Schwab M.E., Caroni P. Oligodendrocytes and CNS myelin are nonpermissive substrates for neurite growth and fibroblast spreading in vitro. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 1988, 8:2381-2393.
58. Sharp J., Frame J., Siegenthaler M., et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants improve recovery after cervical spinal cord injury. Stem Cells 2010, 28:152-163.
59. Sherwood A.M., Dimitrijevic M.R., McKay W.B. Evidence of subclinical brain influence in clinically complete spinal cord injury: Discomplete SCI. Journal of the Neurological Sciences 1992, 110:90-98.
60. Simonen M., Pedersen V., Weinmann O., et al. Systemic deletion of the myelin-associated outgrowth inhibitor Nogo-A improves regenerative and plastic responses after spinal cord injury. Neuron 2003, 38:201-211.
61. Spiess M.R., Muller R.M., Rupp R., et al. Conversion in ASIA impairment scale during the first year after traumatic spinal cord injury. Journal of Neurotrauma 2009, 26:2027-2036.
62. Steward O., Sharp K., Selvan G., et al. A re-assessment of the consequences of delayed transplantation of olfactory lamina propria following complete spinal cord transection in rats. Experimental Neurology 2006, 198:483-499.
63. Steward O., Sharp K., Yee K.M., et al. A re-assessment of the effects of a Nogo-66 receptor antagonist on regenerative growth of axons and locomotor recovery after spinal cord injury in mice. Experimental Neurology 2008, 209:446-468.
64. Sung J.K., Miao L., Calvert J.W., et al. A possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat. Brain Research 2003, 959:29-38.
65. Tanaka H., Yamashita T., Yachi K., et al. Cytoplasmic p21(Cip1/WAF1) enhances axonal regeneration and functional recovery after spinal cord injury in rats. Neuroscience 2004, 127:155-164.
66. Thallmair M., Metz G.A., Z'Graggen W.J., et al. Neurite growth inhibitors restrict plasticity and functional recovery following corticospinal tract lesions. Nature Neuroscience 1998, 1:124-131.
67. Tonges L., Koch J.C., Bahr M., et al. ROCKing regeneration: Rho kinase inhibition as molecular target for neurorestoration. Frontiers in Molecular Neuroscience 2011, 4:39.
68. Wang K.C., Kim J.A., Sivasankaran R., et al. P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 2002, 420:74-78.
69. Wang K.C., Koprivica V., Kim J.A., et al. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 2002, 417:941-944.
70. Weber T., Vroemen M., Behr V., et al. In vivo high-resolution MR imaging of neuropathologic changes in the injured rat spinal cord. American Journal of Neuroradiology 2006, 27:598-604.
71. Weidner N., Ner A., Salimi N., et al. Spontaneous corticospinal axonal plasticity and functional recovery after adult central nervous system injury. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:3513-3518.
72. Wong S.T., Henley J.R., Kanning K.C., et al. A p75(NTR) and Nogo receptor complex mediates repulsive signaling by myelin-associated glycoprotein. Nature Neuroscience 2002, 5:1302-1308.
73. Yamashita T., Higuchi H., Tohyama M. The p75 receptor transduces the signal from myelin-associated glycoprotein to Rho. The Journal of Cell Biology 2002, 157:565-570.
74. Zheng B., Atwal J., Ho C., et al. Genetic deletion of the Nogo receptor does not reduce neurite inhibition in vitro or promote corticospinal tract regeneration in vivo. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:1205-1210.
75. Zheng B., Ho C., Li S., et al. Lack of enhanced spinal regeneration in Nogo-deficient mice. Neuron 2003, 38:213-224.
76. Zorner B., Schwab M.E. Anti-Nogo on the go: From animal models to a clinical trial. Annals of the New York Academy of Sciences 2010, 1198(Suppl. 1):E22-E34.